Moderna Inks 10-Year Manufacturing Deal with Lonza for COVID-19 Vaccine
Moderna has signed a 10-year agreement with Swiss manufacturer Lonza to manufacture its COVID-19 vaccine candidate and other future products.
Under the agreement, the companies will establish manufacturing units at Lonza’s facilities in the U.S. and Switzerland. They plan to expand capacity across Lonza’s worldwide facilities over time to allow for manufacturing of material equivalent to up to 1 billion doses of the vaccine per year.
The companies expect to produce the first batches of the vaccine candidate at Lonza’s U.S. facilities in July.